CellaVision ABCVLLY +12.06%69 Days Inventory is 203.77 as of Mar. 2026, which is 20% above its 10-year median of 170.08. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 786 Medical Devices & Instruments companies, CellaVision AB ranks worse than 50.64% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). CellaVision AB's Average Total Inventories for the
three
months ended in Mar. 2026 was $12.57 Mil. CellaVision AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $5.63 Mil.
Hence, CellaVision AB's Days Inventory for the
three
months ended in Mar. 2026 was 203.77.
The historical rank and industry rank for CellaVision AB's Days Inventory or its related term are showing as below:
CVLLY'
s Days Inventory Range Over the Past 10 Years
Min: 122.79 Med: 170.08 Max: 233.92
Current: 181.55
During the past 13 years, CellaVision AB's highest Days Inventory was 233.92. The lowest was 122.79. And the median was 170.08.
CVLLY's Days Inventory is ranked worse than 50.64% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs CVLLY: 181.55
CellaVision AB's Days Inventory
increased
from Mar. 2025 (185.77) to Mar. 2026 (203.77).
It might indicate that CellaVision AB's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
CellaVision AB's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.45.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CellaVision AB's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.70.
CellaVision AB (OTCPK:CVLLY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
CellaVision AB's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CellaVision AB's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
CellaVision AB Days Inventory Related Terms
CellaVision AB Days Inventory Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a Days Inventory of 203.77 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on CellaVision AB and its competitors. This is 20% above median its historical median of 170.08. Over the past decade, CellaVision AB's Days Inventory has ranged from 122.79 to 233.92. According to the industry distribution chart, CellaVision AB ranks #398 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 50.6%.
Is CellaVision AB's Days Inventory too high?
CellaVision AB's current Days Inventory of 203.77 is 20% above median its 10-year median of 170.08. Over the past 10 years, this metric has ranged from a low of 122.79 to a high of 233.92. The Medical Devices & Instruments industry median Days Inventory is 179.86. CellaVision AB's value of 203.77 is 13.3% above this industry median. Based on the distribution chart, CellaVision AB ranks #398 out of 786 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Days Inventory compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #398 out of 786 companies for Days Inventory. This places CellaVision AB in the lower half of its industry. The industry median Days Inventory is 179.86. CellaVision AB's value of 203.77 is 13.3% above this benchmark. Historically, CellaVision AB's own Days Inventory has ranged from 122.79 to 233.92 over the past decade. While the company's 10-year median is 170.08 vs. the industry median of 179.86, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Days Inventory of 203.77 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Days Inventory is 203.77, which is 20% above median its own 10-year median of 170.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Days Inventory is 203.77, which is 20% above median its 10-year median of 170.08 and 13.3% above the Medical Devices & Instruments industry median of 179.86. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Days Inventory is 203.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Days Inventory: 203.77 (20% above median its 10-year median of 170.08)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 13.3% above the Medical Devices & Instruments median (#398 of 786)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
